ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Lynparza gets FDA approval for ovarian cancer
pharmatimes
December 21, 2018AstraZeneca and MSD have announced that Lynparza (olaparib) has been given the green light by the FDA for first-line maintenance therapy of BRCA-mutated advanced ovarian cancer, further expanding the drug's reach.
Pharma Sources Insight January 2025
